12:28 PM EDT, 08/06/2024 (MT Newswires) -- Exelixis ( EXEL ) said Tuesday the US Food and Drug Administration has accepted its supplemental new drug application for cabozantinib to treat pancreatic neuroendocrine tumors and extra-pancreatic neuroendocrine tumors in previously treated adult patients whose disease is spreading and cannot be treated surgically.

The company said the FDA is due to decide on the application by April 3, 2025. The regulator also granted orphan drug designation to cabozantinib for pancreatic neuroendocrine tumors.

Cabozantinib is currently approved under the Cabometyx brand name for a number of indications, including advanced renal cell carcinoma.

Price: 23.76, Change: +0.24, Percent Change: +1.02